Profitable pills: where to find the best biotech stocks

Marek Poszepczynski of the International Biotechnology Trust highlights three top biotech stocks to buy now.

A professional investor tells us where he'd put his money. This week: Marek Poszepczynski of the International Biotechnology Trust highlights three top biotech stocks.

Biotechnology is rightly classified as a growth sector, but not all companies have the same earnings potential. The drugs addressing the highest unmet medical needs tend to produce significant profits and consistent cash flows. Products that either cure a previously untreatable disease or improve patients' quality of life will sell well and are more likely to benefit from reimbursements by governments and health insurers.

Ideally, the product should be able to maintain a dominant position in its therapeutic area for a long period of time. A company is better able to protect its drug pricing and profitability if it faces fewer competitors. We have selected three stocks to fit these criteria, each with a different risk profile to cater for a variety of risk appetites.

Help for HIV and hepatitis patients

Gilead (Nasdaq: GILD)

But while the overall outlook for Gilead is robust, investors should be aware that the growth potential for this company is slowing as it is hard for such a large firm to expand rapidly. Investors with a higher risk appetite could look to smaller, faster-growing firms such as Vertex or Insmed.

The gold-standard cystic fibrosis drug

Vertex (Nasdaq: VRTX)

As this disease only affects a relatively small number of patients, the company has received orphan-drug status (this is granted to treatments for rare diseases). This allows Vertex to charge a high price for its product and the portfolio is also shielded from competition by Vertex's intellectual-property rights.

A crucial antibiotic

Insmed

(Nasdaq: INSM)

Investing in the antibiotic space has been tough in recent years despite the clear and growing unmet need. However, Insmed has succeeded in developing and launching Arikayce. Initial sales look robust.

Recommended

Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Share tips: eight stocks that should deliver robust returns
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 Dec 2019
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Dec 2019

Most Popular

The Bank of England should create a "Bitpound" digital currency and take the world by storm
Bitcoin

The Bank of England should create a "Bitpound" digital currency and take the world by storm

The Bank of England could win the race to create a respectable digital currency if it moves quickly, says Matthew Lynn.
18 Oct 2020
Don’t miss this bus: take a bet on National Express
Trading

Don’t miss this bus: take a bet on National Express

Bus operator National Express is cheap, robust and ideally placed to ride the recovery. Matthew Partridge explains how traders can play it.
19 Oct 2020
Three stocks that can cope with Covid-19
Share tips

Three stocks that can cope with Covid-19

Professional investor Zehrid Osmani of the Martin Currie Global Portfolio Trust, picks three stocks that he thinks should be able to weather the coron…
12 Oct 2020